Medicare has finished bargaining over the price of 15 widely used prescription drugs, and the government now has a number to show for it. If the newly agreed-upon prices had applied during 2024, Medicare would have spent an estimated $12 billion less on those drugs, a 44 percent cut in net spending. The prices themselves don’t take effect until January 1, 2027, so nobody has actually paid them yet, but the negotiations that set them are over and the size of the gap between old and new pricing is now on the record.
The 15 drugs cover conditions from diabetes and asthma to prostate cancer and bipolar disorder. Some are used by hundreds of thousands of people on Medicare’s Part D drug plans; others by only a few thousand with expensive specialty prescriptions. What ties them together is that each one now has a federally negotiated ceiling price, called a maximum fair price, that a drug company has agreed to honor starting in 2027.
How the Centers for Medicare & Medicaid Services Set Each Price
The 15 drugs were selected for what the agency calls the second cycle of the Medicare Drug Price Negotiation Program, created under the 2022 Inflation Reduction Act. The Centers for Medicare & Medicaid Services sent each participating drug company an initial offer by June 1, 2025, and companies had 30 days to counter. Over the summer and fall, CMS and each manufacturer held three negotiation meetings apiece, trading revised offers back and forth. For eight of the 15 drugs, the two sides settled on a number during those meetings. For the other seven, CMS sent a final written offer in October, and every remaining company accepted it before the deadline. The negotiation period closed on November 1, 2025, with an agreed price for all 15 drugs.
Free retirement updates: Social Security and Medicare change every year, and nobody sends you a memo. Our free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
The $12 Billion Figure Is a Simulation, Not a Bill Already Paid
It helps to be precise about what the $12 billion actually represents. CMS took the negotiated prices that will apply starting in 2027 and ran them backward against actual 2024 Medicare spending, net of rebates and certain fees, to see what the difference would have been. That comparison produced the $12 billion figure and the 44 percent reduction. It’s an estimate built for illustration, not a savings total anyone has banked, since the negotiated prices weren’t in effect in 2024 and won’t be in effect until 2027. CMS also publishes a second, more conservative version of the same math: once spending under the Coverage Gap Discount Program is folded in, the estimated savings drop to $8.5 billion, or about 36 percent lower net spending. Both numbers describe the same 15 drugs; they just account for a different slice of the supply chain.
What Changes for the 5.3 Million People Who Actually Take These Drugs
The aggregate savings estimate is a government-wide number, but a narrower figure is aimed squarely at patients. During 2024, roughly 5.3 million of the 53 million people enrolled in Medicare Part D were dispensed one of these 15 drugs, and they spent a combined $1.7 billion out of their own pockets doing it. CMS projects that once the negotiated prices take hold under the standard Part D benefit design in 2027, people enrolled in Medicare drug coverage would save an estimated $685 million in out-of-pocket costs, collectively, in a comparable year. That’s a small slice of the $12 billion headline figure, because most of the negotiated savings show up in what Medicare itself pays a plan sponsor and a pharmacy, not in what a person hands over at the counter. Someone taking one of the higher-cost drugs on the list, however, could feel a real difference in coinsurance once the new price applies.
The 15 Drugs Ranged From a 38 Percent Discount to an 85 Percent Discount
The negotiated prices aren’t uniform. Across the 15 drugs, the discount off each drug’s 2024 list price for a 30-day supply ranges from 38 percent on one end to 85 percent on the other, depending on the drug, its competition, and how the negotiation played out. Collectively, the 15 selected drugs accounted for $42.5 billion in total Part D gross covered prescription costs in 2024, about 15 percent of all Part D drug spending that year, which is part of why CMS targeted them for the program’s second round. The negotiated prices aren’t frozen once they take effect, either. Starting in the year after they first apply, each price will be adjusted annually by the change in the Consumer Price Index for urban consumers, the same inflation measure used elsewhere in federal benefit programs.
A Third Round Is Already Underway for 2028
The second-cycle prices are locked in, but the program itself keeps moving. CMS has already announced the drug list for its third negotiation cycle, which for the first time includes drugs covered under Medicare Part B in addition to Part D. Those negotiations run through 2026, with any resulting prices scheduled to take effect January 1, 2028. In its announcement of that third round, CMS reaffirmed that the second-cycle prices covered here, the $12 billion estimate among them, remain on track for their January 2027 start date, with no indication the figures or the effective date have shifted since the fact sheet was published in November 2025.
This article was produced with AI assistance and reviewed by a human editor. Figures are linked to their primary sources; where a claim could not be verified from the public record, we say so.
More Financial Reading
